Zevra Therapeutics (NASDAQ:ZVRA) Stock Falls 5.1% – Here’s Why

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) shares dropped 5.1% during mid-day trading on Tuesday. The company traded as low as $10.79 and last traded at $10.7450. 128,543 shares changed hands during trading, a decline of 90% from the average daily volume of 1,252,757 shares. The stock had previously closed at $11.32.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on ZVRA shares. HC Wainwright reissued a “buy” rating and issued a $26.00 target price on shares of Zevra Therapeutics in a report on Thursday, August 20th. Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. BTIG Research reduced their price target on shares of Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a report on Monday, July 27th. Finally, Canaccord Genuity Group dropped their price objective on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating for the company in a report on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $27.14.

Zevra Therapeutics Stock Down 6.7%

The company has a market capitalization of $626.99 million, a PE ratio of 11.46 and a beta of 0.98. The firm’s 50 day simple moving average is $11.54 and its 200 day simple moving average is $11.40.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. The firm had revenue of $39.66 million during the quarter, compared to analyst estimates of $33.88 million. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. As a group, sell-side analysts predict that Zevra Therapeutics, Inc. will post 0.72 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Corey Watton sold 12,300 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $11.25, for a total value of $138,375.00. Following the sale, the director directly owned 1,800 shares in the company, valued at approximately $20,250. This trade represents a 87.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.70% of the stock is currently owned by insiders.

Institutional Trading of Zevra Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. AIGH Capital Management LLC purchased a new position in shares of Zevra Therapeutics in the first quarter worth about $11,184,000. Dimensional Fund Advisors LP increased its holdings in Zevra Therapeutics by 259.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after buying an additional 400,336 shares during the period. Hennion & Walsh Asset Management Inc. raised its position in Zevra Therapeutics by 116.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock worth $5,502,000 after buying an additional 206,543 shares during the last quarter. Janney Montgomery Scott LLC raised its position in Zevra Therapeutics by 16.7% during the 1st quarter. Janney Montgomery Scott LLC now owns 236,834 shares of the company’s stock worth $2,207,000 after buying an additional 33,951 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in Zevra Therapeutics during the 2nd quarter worth approximately $2,846,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines.

Zevra’s lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat.